Dodge & Cox
HZNP

Dodge & Cox’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Dodge & Cox’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,463
Closed -$2.45M – 204
2023
Q1 		$2.45M Buy
+22,463
New +$2.48M ﹤0.01% 137

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Dodge & Cox's HZNP Position: Q2 2023 in Review

Dodge & Cox sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 22,463 shares — an estimated $2.45M sold.

Dodge & Cox first reported a position in HZNP in Q1 2023 and held it in 1 quarter. The position peaked at $2.45M in Q1 2023. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

  • Dodge & Cox reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Dodge & Cox sold 22,463 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $2.45M.
  • Dodge & Cox first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 1 quarter.
  • Dodge & Cox's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.45M in Q1 2023.
  • 517 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Dodge & Cox's 13F filing for Q2 2023, filed 14 Aug 2023.